Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 11/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24285410 | 0.91 | HCAR3 (0.51) | HCAR3NNMTMAPTHCAR2 | |
| SCHEMBL26712399 | 0.88 | HCAR3 (0.50) | HCAR3HCAR2 | |
| SCHEMBL26711594 | 0.87 | HCAR3 (0.49) | HCAR3NNMTHCAR2 | |
| SCHEMBL26712368 | 0.79 | HCAR3 (0.56) | HCAR3NNMTHCAR2 | |
| SCHEMBL26711570 | 0.78 | HCAR3 (0.55) | HCAR3NNMTMAPTHCAR2 | |
| SCHEMBL24285432 | 0.74 | HCAR3 (0.64) | HCAR3NNMTHCAR2 | |
| SCHEMBL10032058 | 0.74 | HCAR3 (0.49) | HCAR3NNMTMAPT | |
| SCHEMBL16865853 | 0.69 | HCAR3 (0.64) | HCAR3NNMTHCAR2 | |
| SCHEMBL31661280 | 0.69 | HCAR3 (0.64) | HCAR3NNMTHCAR2 | |
| SCHEMBL13997668 | 0.68 | PTGS1 (0.41) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339997-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2022052014-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | 上海海聚生物科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339997-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | TP53, ERCC4, SLC19A1 | HCAR3 3677/4885NNMT 3504/4885MAPT 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.